** Drug developer Jasper Therapeutics' JSPR.O shares fall 70.7% to $1.98 premarket
** Company says its experimental drug, briquilimab, achieved a complete response at week 12 in an early-stage study to treat a skin condition called chronic spontaneous urticaria (CSU)
** But the results were affected by an issue with one specific drug product lot
** CSU causes red, itchy bumps on the skin that come and go without a clear reason
** Company says it halted the drug's asthma trial due to the same drug product lot issue
** In the 10 patients with CSU who received the problematic drug product lot, reduction in mean tryptase levels, a marker of mast cell activity, was lower than expected and there was no noticeable improvement, company says
** Jasper is investigating the issue and expects results in the coming weeks
** As of last close, stock down 68.33% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。